Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients

American Journal of Obstetrics and Gynecology

Volumn 181, Issue 1, 1999, Pages 71-79

  Utian, Wulf H ^b   Burry, Kenneth A ^b   Archer, David F ^b   Gallagher, John C ^b   Boyett, Robert L ^a   Guy, Martine ^b   Tachon, Gilles J ^b   Chadha Boreham, Harbajan K ^b   Bouvet, Agnès A ^b  

^a Fournier Research Inc   (United States)

^b NONE

Author keywords

Esclim; Estrogen replacement therapy; Low dose; Menopause; Transdermal patch

Indexed keywords

ESCLIM; ESTRADIOL; FOLLITROPIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; METRORRHAGIA; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEATING; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0003026989     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(99)70438-2     Document Type: Article

References (22)

1. 1. Steingold KA, Laufer L, Chetkowski RJ, De Fazio JD, Matt DW, Meldrum DR, et al. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab 1985;61:627-32.
2. 2. Stampler MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the nurses' health study. N Engl J Med 1991;325:756-62.
3. 3. Studd J, Savvas M, Waston N, Garnett T, Fogelman I, Cooper D. The relationship between plasma estradiol and the increase in bone density in postmenopausal women after treatment with subcutaneous hormone implants. Am J Obstet Gynecol 1990;163:1474-9.
4. 4. Utian WH. Transdermal estradiol overall safety profile. Am J Obstet Gynecol 1987;156:1335-8.
5. 5. Padwick ML, Endacott J, Whitehead MB. Efficacy, acceptability, and metabolic effects of transdermal estradiol in the management of postmenopausal women. Am J Obstet Gynecol 1985;152:1085-91.
6. 6. Place VA, Powers M, Darley PE, Schenkel L, Good WL. A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms. Am J Obstet Gynecol 1985;152:1092-9.
7. 7. Frenkel Y, Kopernik G, Lazer S, Tugendreich D, Zmira N, Oettinger M, et al. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate. Maturitas 1994;20:31-6.
8. 8. Rozenbaum H, Birkhauser M, De Nooyer C, Lambotte R, Pornel B, Schneider H, et al. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm 50). I. Tolerability, adhesion and efficacy. Maturitas 1996;25:161-73.
9. 9. Rozenbaum H, Birkhauser M, De Nooyer C, Lambotte R, Pornel B, Schneider H, et al. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm 50). II. Local skin tolerability, Maturitas 1996;25:175-85.
10. 10. Guidance for clinical evaluation of combination estrogen/progestin-containing drug products used for hormone replacement therapy of postmenopausal women. Rockville (MD): US Food and Drug Administration Hormone Replacement Therapy Working Group; 1995 Mar 20.
11. 11. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
12. 12. Studd JWW, McCarthy K, Zamblera D, Dain MP, Le Lann L. A double-blind, double-dummy, comparative study of Menorest 50 versus Premarin 0.625 mg in the treatment of menopausal symptoms and the prevention of bone loss in patients with menopausal symptoms. Clin Drug Invest 1996;11:205-13.
13. 13. Pornel B, Genazzani AR, Costes D, Dain MP, Le Lann L, Vandepol C. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms; a randomized, multicenter, parallel group study. Maturitas 1995;22:207-18.
14. 14. Lobo RA. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 1991;73:925-30.
15. 15. Field CS, Ory SJ, Walmer HW, Herrmann RR, Judd HL, Riggs BL. Preventive effects of transdermal 17β-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. Am J Obstet Gynecol 1993;168:114-21.
16. 16. Billard TC, Whitcroft SJ, Marsh MS, Ellerington MC, Lees B, Whitehead MI, et al. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporos Int 1994;4:341-8.
17. 17. The Transdermal Hormone Replacement Therapy Investigators Group. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. Int J Fertil 1993;38:5-11.
18. 18. Serfaty D, Caulin F. Efficacy and tolerability of transdermal 17 beta-estradiol in patients with climacteric symptoms: dose titration according to individual choice. Curr Ther Res 1996;57:506-15.
19. 19. Studd J, Panay N, Zamblera D, Leather AT. HRT and long term compliance: the efficacy and safety of Menorest. Int J Gynaecol Obstet 1996;52(Suppl 1):S21-5.
20. 20. Nachtigall LE. Enhancing patient compliance with hormone replacement therapy at menopause. Obstet Gynecol 1990;775(Suppl):77S-80S.
21. 21. Stumpf PG, Trolice MP. Compliance problems with hormone replacement therapy. Obstet Gynecol Clin North Am 1994;21:219-29.
22. 22. Rozenbaum H. New trends in HRT. In: Kennedy TE, editor. European Union of General Practitioners reference book 1997/98. 4th ed. London: Kensington Publications; 1997, p. 369.